title: Counterpoint: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? No.
authors.affiliation: The David Geffen School of Medicine at UCLA, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA. Electronic address: jhansen@labiomed.org.
authors.forename: James E
authors.initials: JE
authors.lastname: Hansen
authors.affiliation: The David Geffen School of Medicine at UCLA, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
authors.forename: Janos
authors.initials: J
authors.lastname: Porszasz
mesh_terms: D001249:Asthma / Q000175:diagnosis / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000494:pharmacology*; D003937:Diagnosis, Differential; D005541:Forced Expiratory Volume / Q000502:physiology*; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000502:physiology*; D009929:Organ Size; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000503:physiopathology; D015203:Reproducibility of Results; D012129:Respiratory Function Tests; D012680:Sensitivity and Specificity; D013147:Spirometry; D014797:Vital Capacity / Q000502:physiology*
chemical_list: D001993:Bronchodilator Agents